[en] Gliomas are incurable brain cancers with poor prognosis, with epigenetic dysregulation being a distinctive feature. 5-hydroxymethylcytosine (5-hmC), an intermediate generated in the demethylation of 5-methylcytosine, is present at reduced levels in glioma tissue compared with normal brain, and that higher levels of 5-hmC are associated with improved patient survival. DNA demethylation is enzymatically driven by the ten-eleven translocation (TET) dioxygenases that require ascorbate as an essential cofactor. There is limited data on ascorbate in gliomas and the relationship between ascorbate and 5-hmC in gliomas has never been reported. Clinical glioma samples (11 low-grade, 26 high-grade) were analysed for ascorbate, global DNA methylation and hydroxymethylation, and methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter. Low-grade gliomas contained significantly higher levels of ascorbate than high-grade gliomas (p = 0.026). Levels of 5-hmC were significantly higher in low-grade than high-grade glioma (p = 0.0013). There was a strong association between higher ascorbate and higher 5-hmC (p = 0.004). Gliomas with unmethylated and methylated MGMT promoters had similar ascorbate levels (p = 0.96). One mechanism by which epigenetic modifications could occur is through ascorbate-mediated optimisation of TET activity in gliomas. These findings open the door to clinical intervention trials in patients with glioma to provide both mechanistic information and potential avenues for adjuvant ascorbate therapy.
Disciplines :
Oncology
Author, co-author :
Crake, Rebekah ; Université de Liège - ULiège > GIGA > GIGA Cancer - Metastases Research Laboratory ; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand
Burgess, Eleanor R; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand
Wiggins, George A R; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand
Magon, Nicholas J; Centre for Free Radical Research, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand
Das, Andrew B; Centre for Free Radical Research, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand ; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, Australia ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia
Vissers, Margreet C M; Centre for Free Radical Research, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand
Morrin, Helen R; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand ; Cancer Society Tissue Bank, University of Otago Christchurch, Christchurch, New Zealand
Royds, Janice A; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
Slatter, Tania L; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
Robinson, Bridget A; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand ; Canterbury Regional Cancer and Haematology Service, Canterbury District Health Board, Christchurch, New Zealand ; Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Phillips, Elisabeth; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand
Dachs, Gabi U; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand. gabi.dachs@otago.ac.nz
Language :
English
Title :
Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine.
CMRF - Canterbury Medical Research Foundation [NZ] University of Otago. Division of Health Sciences [NZ] Mackenzie Charitable Foundation [NZ]
Funding text :
Funding was obtained from the Canterbury Medical Research Foundation, the University of Otago Research Grants and the Mackenzie Charitable Foundation.We are grateful to the patients with brain cancer who gifted their tumours to research. We also thank He Taonga Tapu Cancer Society Tissue Bank for collecting and processing of samples, Dr Juliet Pullar for help with ascorbate analysis, biostatistician Associate Professor John Pearson (University of Otago, Christchurch) for statistical advice, and the University of Otago for EB’s doctoral scholarship.
Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131, 803–820 (2016).
Wesseling, P. & Capper, D. WHO 2016 classification of gliomas. Neuropathol. Appl. Neurobiol. 44, 139–150 (2018).
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
Hou, L. C., Veeravagu, A., Hsu, A. R. & Tse, V. C. Recurrent glioblastoma multiform: a review of natural history and management options. Neurosurg. Focus 20(4), E5 (2006).
Molinaro, A. M., Taylor, J. W., Wiencke, J. K. & Wrensch, M. R. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol. 15(7), 405–417 (2019).
Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18(3), 170–186 (2021).
Becker, A. P., Sells, B. E., Haque, S. J. & Chakravarti, A. Tumor heterogeneity in glioblastomas: From light microscopy to molecular pathology. Cancers (Basel) 13(4), 761 (2021).
Louis, D. N. et al. cIMPACT-NOW update 6: New entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 30(4), 844–856 (2020).
Raiber, E. A. et al. Base resolution maps reveal the importance of 5-hydroxymethylcytosine in a human glioblastoma. NPJ Genom. Med. 2, 6 (2017).
Kohli, R. M. & Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 472–479 (2013).
Carella, A. et al. Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis. Int. J. Cancer. 146(2), 373–387 (2020).
Stasik, S. et al. Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild- type glioblastoma. Neoplasia 22(12), 800–808 (2020).
Laffaire, J. et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol. 13(1), 84–98 (2011).
Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5), 510–522 (2010).
Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390), 479–483 (2012).
Dunn, J. et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer 101(1), 124–131 (2009).
Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003 (2005).
Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
Zhao, Y. H. et al. The clinical significance of O6-Methylguanine-DNA methyltransferase promoter methylation status in adult patients with glioblastoma: A meta-analysis. Front. Neurol. 9, 127 (2018).
Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19), 1350–1354 (2000).
Pegg, A. E., Dolan, M. E. & Moschel, R. C. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog. Nucl. Acid Res. Mol. Biol. 51(1), 167–223 (1995).
Orr, B. A., Haffner, M. C., Nelson, W. G., Yegnasubramanian, S. & Eberhart, C. G. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS ONE 7(7), e41036 (2012).
Mur, P. et al. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. J. Neuro-Oncol. 122(3), 441–450 (2015).
Chen, B. et al. Repression of the expression of TET2 by ZEB1 contributes to invasion and growth in glioma cells. Mol. Med. Rep. 15(5), 2625–2632 (2017).
García, M. G. et al. Epigenetic dysregulation of TET2 in human glioblastoma. Oncotarget 9(40), 25922–25934 (2018).
Crake, R. L. I. et al. The role of 2-oxoglutarate dependent dioxygenases in gliomas and glioblastomas: a review of epigenetic reprogramming and hypoxic response. Front. Oncol. 11, 619300 (2021).
Minor, E. A., Court, B. L., Young, J. I. & Wang, G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J. Biol. Chem. 288(19), 13669–13674 (2013).
Blaschke, K. et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500(7461), 222–226 (2013).
Gustafson, C. B. et al. Epigenetic reprogramming of melanoma cells by vitamin C treatment. Clin. Epigenetics 7, 51 (2015).
Shenoy, N. et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. J. Clin. Invest. 130, 1612–1625 (2019).
Landolt, H., Langemann, H., Probst, A. & Gratzl, O. Levels of water-soluble antioxidants in astrocytoma and in adjacent tumor-free tissue. J. Neurooncol. 21, 127–133 (1994).
Burgess, E. R. et al. Increased ascorbate content of glioblastoma is associated with a suppressed hypoxic response and improved patient survival. Front. Oncol. 12, 829524 (2022).
Wu, Y.-C. & Ling, Z.-Q. The role of TET family proteins and 5-hydroxymethylcytosine in human tumors. Histol. Histopathol. 29, 991–997 (2014).
Kim, A. R. et al. Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma. Oncoimmunology 11(1), 2026019 (2022).
Hung, N. A. et al. Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma. Mod. Pathol. 29(3), 212–226 (2016).
Rice, M. E. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci. 23(5), 209–216 (2000).
Agathocleous, M. et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549(7673), 476–481 (2017).
Kuiper, C. et al. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res. 70(14), 5749–5758 (2010).
Kuiper, C. et al. Increased tumor ascorbate is associated with extended disease-free survival and decreased Hypoxia-Inducible Factor-1 activation in human colorectal cancer. Front. Oncol. 4, 10 (2014).
Campbell, E. J. et al. Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer 19(1), 307 (2019).
Wohlrab, C. et al. Ascorbate modulates the hypoxic pathway by increasing intracellular activity of the HIF hydroxylases in renal cell carcinoma cells. Hypoxia (Auckl) 7, 17–31 (2019).
Jóźwiak, P. et al. Expression of hypoxia inducible factor 1α and 2α and its association with vitamin C level in thyroid lesions. J. Biomed. Sci. 24(1), 83 (2017).
Korkolopoulou, P. et al. Hypoxia-inducible factor 1a/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. 30, 267–278 (2004).
Kuiper, C., Vissers, M. C. & Hicks, K. O. Pharmacokinetic modeling of ascorbate diffusion through normal and tumor tissue. Free Radic. Biol. Med. 77, 340–352 (2014).
Campbell, E. J. et al. Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. Free Radic. Biol. Med. 99, 451–462 (2016).
Dewhirst, M. W. Concepts of oxygen transport at the microcirculatory level. Semin. Radiat. Oncol. 8(3), 143–150 (1998).
Booth, M. J. et al. Oxidative bisulfite sequencing of 5-methylcytosine and 5- hydroxymethylcytosine. Nature Protoc. 8(10), 1841–1851 (2013).
Iurlaro, M. et al. A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol. 14(10), R119 (2013).
Spruijt, C. G. et al. Dynamic readers for 5-(Hydroxy)methylcytosine and its oxidized derivatives. Cell 152(5), 1146–1159 (2013).
Waha, A. et al. Nuclear exclusion of TET1 is associated with loss of 5- hydroxymethylcytosine in IDH1 wild-type gliomas. Am. J. Pathol. 181(2), 675–683 (2012).
Mikirova, N. et al. High-dose intravenous vitamin C treatment of a child with neurofibromatosis type 1 and optic pathway glioma: A case report. Am. J. Case Rep. 17, 774–781 (2016).
Baillie, N., Carr, A. C. & Peng, S. The use of intravenous vitamin C as a supportive therapy for a patient with glioblastoma multiforme. Antioxidants 7, 115 (2018).
Bodeker, K. L. et al. First in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. Clin. Cancer Res. 25, 6590–6597 (2019).
May, J. M. Vitamin C transport and its role in the central nervous system. Sub-cell Biochem. 56, 85–103 (2012).
Lykkesfeldt, J. & Tveden-Nyborg, P. The pharmacokinetics of vitamin C. Nutrients 11(10), 2412 (2019).
Tallaksen, C. M., Bøhmer, T. & Bell, H. Concentrations of the water-soluble vitamins thiamin, ascorbic acid, and folic acid in serum and cerebrospinal fluid of healthy individuals. Am. J. Clin. Nutr. 56(3), 559–564 (1992).
Zang, L., Kondengaden, S. M., Che, F., Wang, L. & Heng, X. Potential epigenetic-based therapeutic targets for glioma. Front. Mol. Neurosci. 11, 408 (2018).
Tucker, D. W. et al. Epigenetic reprogramming strategies to reverse global loss of 5-hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous ovarian cancer. Clin. Cancer Res. 24(6), 1389–1401 (2018).
Huang, R. et al. Restoration of TET2 deficiency inhibits tumor growth in head neck squamous cell carcinoma. Ann. Transl. Med. 8(6), 329 (2020).
Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170(6), 1079-1095.e20 (2017).
Peng, D. et al. Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer. Clin. Epigenetics 10(1), 94 (2018).
Eyres, M. et al. TET2 drives 5hmC marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes. Gastroenterology 161(2), 653-668.e16 (2021).
Gillberg, L. et al. Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes. Clin. Epigenetics 11(1), 143 (2019).
Malley, D. S. et al. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol. 121(5), 651–661 (2011).
Johannessen, L. E. et al. MGMT Gene promoter methylation status - assessment of two pyrosequencing kits and three methylation-specific PCR methods for their predictive capacity in glioblastomas. Cancer Genomics Proteomics 15(6), 437–446 (2018).
